Articles

An explosion of research in the field led to the approval of pemigatinib in April 2020 for patients with unresectable, previously treated advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement.

Pemigatinib Trial Seeks to Build on Targeted Advances in Cholangiocarcinoma

Videos

Grzegorz S. Nowakowski, MD, discusses the rationale for the ongoing, randomized phase 3 ENGINE study in diffuse large B-cell lymphoma.

Dr. Nowakowski on the Rationale of the ENGINE Trial in DLBCL

Thorvardur (Thor) Halfdanarson, MD, discusses investigational agents that are being evaluated in patients with colorectal cancer who do not harbor genomic alterations.  



Dr. Halfdanarson on Investigational Agents in Driver-Negative CRC

Thorvardur (Thor) Halfdanarson, MD, discusses the KEYNOTE-177 trial in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer.

Dr. Halfdanarson on the KEYNOTE-177 Trial in MSI-H/dMMR mCRC 

Grzegorz S. Nowakowski, MD, discusses the rationale for reevaluating the PCKß inhibitor enzastaurin in diffuse large B-cell lymphoma. 



Dr. Nowakowski on the Rationale for Reevaluating Enzastaurin in DLBCL

Thorvardur (Thor) Halfdanarson, MD, discusses the molecular differences between left- versus right-sided tumors in colorectal cancer.

Mayo Clinic Cancer Center

Latest from Mayo Clinic Cancer Center

New content coming soon, please check back later.